Search

Pipamperone

It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518]. … In an effort to improve [haloperidol]'s pharmacological effects, Janssen discovered that pipamperone, an agent whose pharmacological profile was distinct from haloperidol and all other known antipsychotic

ALT-2074

An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. … BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.

Methyl 2,5-dihydroxycinnamate

Ergothioneine

8-chlorotheophylline

Because adenosine causes a decrease in neuronal firing, blockade of the adenosine receptor causes the reverse effect resulting in excitation. … Its main use is in combination with [Diphenhydramine] as the antiemetic drug [Dimenhydrinate].

4-dimethylaminophenol

Gleptoferron

Colloid solution of ferric hydroxide, dextran & glucoheptonic acid.

TAS-106

TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours [A31693].

AV608

AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).

Afelimomab

Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.